share_log

Oppenheimer Maintains Outperform on Inovio Pharmaceuticals, Lowers Price Target to $15

Oppenheimer Maintains Outperform on Inovio Pharmaceuticals, Lowers Price Target to $15

奥本海默对伊诺维奥制药维持跑赢大盘评级,并将目标价格下调至15美元
Benzinga ·  11/18 08:55  · 评级/大行评级

Oppenheimer analyst Jay Olson maintains Inovio Pharmaceuticals (NASDAQ:INO) with a Outperform and lowers the price target from $33 to $15.

Oppenheimer的分析师Jay Olson维持伊诺维奥制药(纳斯达克:INO)的评级为表现优于大盘,并将目标价格从33美元下调至15美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发